Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

Looking ahead to 2025, AbbVie projects adjusted earnings per share between $12.12 and $12.32, reflecting strong confidence in its growth strategy. The company has significantly raised its long-term ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

AbbVie Inc.'s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie (ABBV) reported better-than-expected fourth-quarter results on Friday amid robust sales of Skyrizi and Rinvoq, prompting the drugmaker to lift its long-term combined revenue outlook for the two ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...